Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment

Bone

Volumn 22, Issue 5, 1998, Pages 559-564

  Ravn, P ^a   Christensen, J O ^a   Baumann, M ^b   Clemmesen, B ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bisophosphonate; Bone turnover; Ibandronate; Postmenopausal osteoporosis; Prediction; Withdrawal

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; IBANDRONIC ACID; OSTEOCALCIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FEMUR; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEOPENIA; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SPINE; STATISTICAL ANALYSIS;

AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FEMUR; FOLLOW-UP STUDIES; FOREARM; HUMANS; MIDDLE AGED; OSTEOCALCIN; PEPTIDES; SPINE;

EID: 0031970445     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(98)00044-1     Document Type: Article

References (39)

1. Adami, S., Passeri, M., Ortolani, S., et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 17:383-390; 1995.
2. Bjarnason, K., Hassager, C., Ravn, P., and Christiansen, C. Early postmenopausal diminution of forearm and spinal bone mineral density: A cross-sectional study. Osteopor Int 5:35-38; 1995.
3. Bonde, M., Qvist, P., Fledelius, C., Riis, B. J., and Christiansen, C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:2022-2025; 1994.
4. ™): Follow up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80:864-868; 1995.
5. Bone, H. G., Downs, R. W., Jr., Tucci, J. R., et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 82:265-274; 1997.
6. Civitelli, R., Gonelli, S., Zacchei, F., Bigazzi, S., Vattimo, A., Avioli, L. V., and Gennari, C. Bone turnover in postmenopausal osteoporosis: Effect of calcitonin treatment. J Clin Invest 82:1268-1274; 1988.
7. Committee of Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology. Recommended methods for the determination of four enzymes in blood. Scan J Clin Lab Invest 33:291-306; 1974.
8. Delmas, P. D. Biochemical markers of bone turnover for the clinical investigation of osteoporosis. Osteopor Int 3(Suppl 1):81-86; 1993.
9. Delmas, P. D. Biochemical markers of bone turnover. J Bone Miner Res 8(Suppl 2):S549-S555; 1993.
10. Devogelaer, J. P., Broll, H., Correa-Rotter, R., et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal osteoporosis. Bone 18:141-150; 1996.
11. Garnero, P., Gineyts, E., Arbault, P., Christiansen, C., and Delmas, P. D. Different effect of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 10:641-649; 1995.
12. Garnero, P., Gineyts, E., Riou, J. P., and Delmas, P. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785; 1994.
13. Garnero, P., Shih, W. J., Gineyts, E., Karpf, D. B., and Delmas, P. D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700; 1994.
14. Garnero, P., Sornay-Rendu, E., Chapuy, M.-C., and Delmas, P. D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337-349; 1996.
15. Genant, H. K., Engelke, K., Fuerst, T., et al. Noninvasive assessment of bone mineral and structure: State of the art. J Bone Miner Res 11:707-730; 1996.
16. Giannini, S., D'angelo, A. D., Malvasi, L., et al. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 14:137-141; 1993.
17. Han, I. K., Ahn, Y. J., and Min, Y. K. Response of hormone replacement therapy on bone mineral density according to serum levels of osteocalcin. J Bone Miner Res 17:8113; 1992.
18. Harris, S. T., Gertz, B. I, Genant, H. K., et al. The effect of short-term treatment with alendronate upon vertebral density and biochemical markers of bone remodelling in early postmenopausal women. J Clin Endocrinol Metab 76:1399-1406; 1993.
19. Harris, S. T., Watts, N. B., Jackson, R. D., et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95:557-567; 1993.
20. Heaney, R. B. The bone-remodeling transient: Implications for the interpretation of clinical studies of bone mass changes. J Bone Miner Res 9:1515-1519; 1994.
21. Liberman, U. A., Weiss, S. R., Bröll, J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443; 1995.
22. Morgenthaler, J. J. Western blots of immune globulin preparations for intravenous use. Transfusion 27:369-370; 1987.
23. Nielsen, N. M., Recke, P. V., Hansen, M. A., Overgaard, K., and Christiansen, C. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. Calcif Tissue Int 55:8-11; 1994.
24. Orwoll, E. S., Oviatt, S. K., and the Nafarelin/Bone Study Group. Longitudinal precision of dual-energy X-ray absorptiometry in a multicenter study. J Bone Miner Res 6:191-197; 1991.
25. Parfitt, A. M. The coupling of bone formation to resorption: A critical analysis of the concept and its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res 4:1-6; 1982.
26. Ravn, P., Clemmesen, B., Riis, B. J., and Christiansen, C. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 19: 527-533; 1996.
27. Ravn, P., Hetland, M. L., Overgaard, K., and Christiansen, C. Pre- and postmenopausal changes in bone mineral density of the proximal femur measured by dual energy x-ray absorptiometry. J Bone Miner Res 9:1975-1980; 1994.
28. Reginster, J. Y., Lecart, M. P., Deroisy, R., et al. Prevention of postmenopausal bone loss by tiludronate. Lancet ii:1469-1471; 1989.
29. Reid, I. R., Wattie, D. J., Evans, M. C., Gamble, G. D., Stapleton, J. P., and Cornish, J. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal ossteoporosis. J Clin Endocrinol Metab 79:1595-1599; 1994.
30. Riis, B. J. Biochemical markers of bone turnover. II: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 95:17S-21S; 1993.
31. Riis, B. J., Overgaard, K., and Christiansen, C. Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Osteopor Int 5:267-280; 1995.
32. Rosenquist, C., Qvist, P., Bjarnason, N., and Christiansen, C. Measurement of a more stable structure of osteocalcin in human serum using two monoclonal antibodies in an enzyme-linked immunosorbent assay (ELISA). Clin Chem 41:1439-1445; 1995.
33. Ross, P. D., Davis, J. W., Vogel, J. M., and Wasnich, R. A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tissue Int 46:149-161; 1990.
34. Rossini, M., Gatti, D., Zamberlan, N., Braga, V., Dorizzi, R., and Adami, S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 9:1833-1837; 1994.
35. SAS Institute. SAS/STAT guide for personal computers, Version 6. Cary: SAS Institute; 1987.
36. Storm, T., Thamsborg, G., Steinice, T., Genant, H. K., and Sorensen, O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopsual osteoporosis. N Engl J Med 322:1265-1271; 1990.
37. Valkema, R., Vismans, F.-J. F. E., Papapoulos, S. E., Pauwels, E. K. J., and Bijvoet, O. L. M. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 5:183-192; 1989.
38. Wang, Q., Hassager, C., Ravn, P., Wang, S., and Christiansen, C. Total and regional body composition changes in arly postmenopausal women: Age-related or menopausal-related? Am J Clin Nutr 60:843-848; 1994.
39. Watts, N. B., Harris, S. T., Genant, H. K., et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79; 1990.